Copenhagen, October 26, 2023 — In a landmark move set to reshape the Nordic biotech landscape, Swedish private equity firm Nordic Capital and UK-based Permira have launched a joint bid to acquire Danish vaccine manufacturer Bavarian Nordic A/S in a deal valued at approximately DKK 19 billion (roughly $2.8 billion). The offer, priced at DKK 233 per share, represents a significant premium and underscores growing investor confidence in the global vaccine sector, particularly in the wake of recent mpox (monkeypox) outbreaks.
Bavarian Nordic, best known for its development and production of the Jynneos vaccine—a smallpox and mpox vaccine—has emerged as a key player in public health preparedness over the past two years. With mpox declared a public health emergency of international concern by the World Health Organization in 2022, demand for the company’s flagship product surged, catapulting Bavarian Nordic into the global spotlight and significantly boosting its financial performance.
The proposed acquisition comes amid strong financial projections for the company. Bavarian Nordic has forecast 2023 revenues between DKK 5.7 billion and DKK 6.7 billion ($840 million–$990 million), driven largely by international government contracts and stockpiling initiatives. The company, headquartered in Kvistgard near Copenhagen, employs over 800 people and operates state-of-the-art manufacturing facilities in Denmark and the United States.
In a statement released this morning, Luc Debruyne, Chairman of the Board at Bavarian Nordic, confirmed that the Board intends to recommend the offer to shareholders. “After careful evaluation, we believe this transaction represents a compelling opportunity for our shareholders,” Debruyne said. “Nordic Capital and Permira bring not only financial strength but also deep experience in scaling life science companies. Their long-term vision aligns with our mission to protect global health through innovative vaccines.”
The all-cash offer of DKK 233 per share represents a 43% premium over Bavarian Nordic’s 30-day volume-weighted average share price prior to the announcement. Despite the attractive offer, the market responded with enthusiasm: Bavarian Nordic’s shares rose sharply in early trading, briefly surpassing the offer price to reach DKK 237.80—a sign of investor speculation that a bidding war or improved offer could emerge.
Nordic Capital, which has a strong track record in healthcare investments across Northern Europe, and Permira, a global private equity leader with a focus on technology and healthcare, emphasized their commitment to maintaining Bavarian Nordic’s operational base in Denmark and supporting its R&D pipeline. The companies stated their intention to help accelerate the development of next-generation vaccines, including candidates for cancer immunotherapies and emerging infectious diseases.
“This is not just a financial investment—it’s a strategic commitment to one of Europe’s most innovative biotech firms,” said a joint spokesperson for the two funds. “Bavarian Nordic has proven its ability to respond rapidly to public health threats. We believe there is significant potential to expand its global footprint and bring new vaccines to market faster.”
Regulatory approvals and shareholder consent are required before the deal can close, with the process expected to conclude in the first half of 2024. The acquisition would mark one of the largest private equity takeovers of a Danish pharmaceutical company in recent years and could signal a broader trend of consolidation in the European life sciences sector.
Analysts at Danske Bank noted in a morning briefing that while the offer is generous, the company’s long-term growth prospects—especially in pandemic preparedness and oncology—may justify even higher valuations. “Bavarian Nordic is more than a vaccine supplier; it’s a strategic asset in global health security,” said healthcare analyst Mette Iversen. “This deal could be the beginning of a new chapter, not just for the company, but for Denmark’s position in the global biotech arena.”
As governments worldwide reassess their pandemic readiness, the spotlight on vaccine innovators like Bavarian Nordic is unlikely to fade. With deep-pocketed private equity backing, the Danish firm may soon be poised to expand its influence far beyond its current reach—transforming from a niche player into a cornerstone of global health infrastructure.
For ongoing updates on this developing story, subscribe to The Nordic Business Journal Newsletter.